clinical trial · NCT07093255
Safety, PK and PD of FLQ-101 in Premature Neonates
Retinopathy of Prematurity (ROP)FLQ-101
brief summary
The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.
started
Apr 3, 2026
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Apr 21, 2026
official title
A Phase 1b, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of FLQ-101 in Premature Neonates at High Risk of Developing ROP
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol